NATCO records FY23 PAT at Rs. 715.3 Cr

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.

Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239

Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr

US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Kristin Judge Joins Emmes as Chief Growth Officer

Eugia Pharma receives USFDA approval for Carboprost Tromethamine Injection

The product is expected to be launched in June 2023

Labindia partners with Hamilton Laboratory to launch ‘Labindia Hamilton’

Product deliveries scheduled in Q3 of 2023

Lincoln Pharmaceuticals posts FY23 PAT at Rs. 72.90 Cr

For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year

Lupin Diagnostics Launches Satellite Laboratory in Vijayawada

Continues to Expand its Presence in South India

Mandaviya addresses 76th World Health Assembly

The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world